Rophibio, Inc.
Biotechnology company developing biosimilars and biopharmaceuticals including gene- and cell-based therapies. Maintains candidate pipelines for biosimilars and novel biologics, conducts global clinical development and regulatory submissions for late-stage trials, and performs process development for biologic products. Engages in industry partnerships and has secured external investment.
Industries
N/A
Nr. of Employees
small (1-50)
Rophibio, Inc.
6th Floor, Room 618, 33 Research Park-ro 55beon-gil, Yeonsu-gu, Incheon, South Korea (Songdo-dong)
Patents
Anti-STAT3 specific antibody and the pharmaceutical composition comprising thereof
US-12116403-B2
View DetailsAnti-STAT3 bispecific antibody having cell-penetrating ability, and pharmaceutical composition containing same
US-11186631-B2
View Details
Anti-STAT3 specific antibody and the pharmaceutical composition comprising thereof
US-12116403-B2
View DetailsAnti-STAT3 bispecific antibody having cell-penetrating ability, and pharmaceutical composition containing same
US-11186631-B2
View DetailsProducts
Biosimilar candidate pipeline
Pipeline of biosimilar development programs across multiple therapeutic areas, advanced into late-stage clinical development.
Biopharmaceutical (novel) candidate pipeline
Pipeline of novel biopharmaceuticals including gene- and cell-therapy candidates for therapeutic development.
Biosimilar candidate pipeline
Pipeline of biosimilar development programs across multiple therapeutic areas, advanced into late-stage clinical development.
Biopharmaceutical (novel) candidate pipeline
Pipeline of novel biopharmaceuticals including gene- and cell-therapy candidates for therapeutic development.
Expertise Areas
- Biosimilar development
- Biopharmaceutical R&D (including gene and cell therapies)
- Clinical development and regulatory submissions for late-stage trials
- Process development for biologics (monoclonal antibodies)
Key Technologies
- Biosimilar development
- Gene and cell therapy platforms
- Monoclonal antibody process development
- Clinical IND submission workflows
News & Updates
Company secured first overseas investment from a European pharmaceutical firm.
Domestic IND approval granted for Phase III study of 'RBS-001'.
IND approval in Europe for a biosimilar of aflibercept (Eylea) to proceed to Phase III.
U.S. FDA IND approval for Phase III clinical trial of an aflibercept biosimilar.
Announcement of process development collaboration with a partner company for a pembrolizumab (Keytruda) biosimilar.
Completed global submission to initiate Phase III clinical development for an aflibercept biosimilar.
Company secured first overseas investment from a European pharmaceutical firm.
Domestic IND approval granted for Phase III study of 'RBS-001'.
IND approval in Europe for a biosimilar of aflibercept (Eylea) to proceed to Phase III.
U.S. FDA IND approval for Phase III clinical trial of an aflibercept biosimilar.
Announcement of process development collaboration with a partner company for a pembrolizumab (Keytruda) biosimilar.
Completed global submission to initiate Phase III clinical development for an aflibercept biosimilar.